What it is
Dactinomycin is a chromopeptide antibiotic: a flat, coloured ring system (a phenoxazinone) carrying two identical rings of five amino acids, each closed into a lactone. That description is PubChem's structure name for CID 457193, and the label calls it "an actinomycin" produced by Streptomyces parvullus. It is the best-known member of the actinomycins, which is why it is also called actinomycin D.
| Property | Value | Source |
|---|---|---|
| Formula | C62H86N12O16 | PubChem CID 457193; label |
| Molecular weight | 1,255.42 Da | Label |
| Structure | Phenoxazinone core + two cyclic pentapeptide lactones | PubChem structure name |
| Producer | Streptomyces parvullus | Label |
| Vial | 500 mcg dactinomycin + 20 mg mannitol, lyophilised | Label |
How it acts. The label's summary is that it "binds DNA and inhibits RNA synthesis"; cells that are dividing fast depend most on making RNA, which is why it is used against cancers. Its nearest relative in the library is bleomycin, another peptide-derived antibiotic from Streptomyces, which breaks DNA rather than blocking RNA. Other peptide-based cancer drugs in the library work on the proteasome instead: bortezomib and carfilzomib.
What the label covers
Per the Meitheal label (effective 2020-11-13), dactinomycin is indicated for:
| Use | How the label places it | Example label dose |
|---|---|---|
| Wilms tumour | Multi-phase combination chemotherapy, adult and paediatric | 45 mcg/kg IV every 3–6 weeks, up to 26 weeks |
| Rhabdomyosarcoma | Combination chemotherapy | 15 mcg/kg IV daily × 5, every 3–9 weeks |
| Ewing sarcoma | Combination chemotherapy | 1,250 mcg/m² IV every 3 weeks |
| Metastatic nonseminomatous testicular cancer | With cisplatin-based chemotherapy | 1,000 mcg/m² IV every 3 weeks |
| Gestational trophoblastic neoplasia | Single agent or combination | 12 mcg/kg IV daily × 5 (low risk) |
| Regional perfusion | With melphalan, lower or upper limb or pelvis | 50 or 35 mcg/kg once |
These are the label's figures, reported as written; the regimen for any patient is set by an oncology team.
The label's pharmacokinetic data rest on three people. Its distribution and excretion section comes from radiolabelled dactinomycin given to three adults with malignant melanoma: it concentrated in nucleated cells, did not cross the blood–brain barrier, and about 30% was recovered in urine and faeces within a week.
What the trials showed
- Gestational trophoblastic neoplasia. In GOG-0174, 240 women were enrolled and 216 eligible; biweekly IV dactinomycin 1.25 mg/m² gave complete responses in 70% against 53% for weekly IM methotrexate 30 mg/m² (P = .01). Both regimens were less effective at WHO risk score 5–6 or with choriocarcinoma (the abstract reports complete responses of 9% and 42%) (Osborne et al. 2011, PMID 21263100).
- Wilms tumour. NWTS-4 randomised 1,687 children to single-dose "pulse-intensive" or 5-day divided-dose dactinomycin (with vincristine, and doxorubicin in high-risk disease). Two-year relapse-free survival was 91.3% v 91.4% in low-risk and 87.3% v 90.0% in high-risk patients; the authors recommended the single-dose schedule as the new standard, citing equal efficacy, less severe blood toxicity and fewer visits (Green et al. 1998, PMID 9440748).
Risks the label lists
Secondary cancers including leukaemia; severe or fatal hepatic veno-occlusive disease, with higher risk under age 4 or with radiotherapy; extravasation injury; myelosuppression; severe mucocutaneous reactions; renal toxicity and hepatotoxicity; potentiation of radiation toxicity and radiation recall (the label calls for a 50% dose reduction with concurrent radiation); and embryo-fetal toxicity. Live viral vaccines are not recommended before or during treatment. Common reactions include infection, hair loss, rash, nausea, vomiting, low blood counts and mouth sores.
Where it stands
Dactinomycin is an old, approved chemotherapy still in standard regimens for several childhood and gynaecological cancers. The Cosmegen brand (NDA 050682) is listed as discontinued in Drugs@FDA; four generic versions, with original approvals dated 2017–2020, are listed. Treatment decisions belong to an oncology team; this entry records what the compound is and what its label and trials state.
Not opened for this entry: the original 1960s approval documents and the history of the actinomycins' discovery; the date shown above is the oldest submission on the Drugs@FDA file, not a confirmed approval date.
Sources opened 2026-11-19: openFDA drug label (Meitheal dactinomycin for injection, effective 2020-11-13); Drugs@FDA via openFDA (NDA 050682 and four ANDAs); PubChem (CID 457193); PubMed E-utilities (count; abstracts of PMIDs 21263100, 9440748); ClinicalTrials.gov API v2.
